JPRN-jRCT2080220821未知3 期
ong-Term Safety Study of KW-6002 in the Treatment of Parkinson's Disease (Phase 3)
Kyowa Hakko Kirin Co., Ltd.0 个研究点目标入组 150 人开始时间: 2009年8月18日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Be willing and able to give written informed consent
- •2. Completion of the study 6002-009
排除标准
- •1. Mini-mental status examination score of 23 or less
- •2. Less than 70% of compliance in the study 6002-009
- •3. Emergency deviation in the study 6002-009
- •4. Pregnant females
研究者
相似试验
未知
3 期
Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500 (6500-004)Parkinson's DiseaseJPRN-jRCT2080220980Kyowa Hakko Kirin Co., Ltd.20
已完成
3 期
Long-Term Safety Study of KW-6500 in Patients With Parkinson's DiseaseParkinson's DiseaseNCT00955318Kyowa Kirin Co., Ltd.58
已完成
不适用
Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose-E213 Hyperparathyroidism, unspecifiedHyperparathyroidism, unspecifiedE213PER-005-09ABBOTT LABORATORIOS S.A.,30
未知
3 期
ong-term study of KW-6485P (6485P-005)Symptomatic or cryptogenic localization-related epilepsyJPRN-jRCT2080221336Kyowa Hakko Kirin Co., Ltd.60
未知
2 期
ong-term study of KW-6485PSymptomatic or cryptogenic localization related epilepsyJPRN-jRCT2080220855Kyowa Hakko Kirin Co., Ltd.25